Search Results

• • 72 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Edatrexate (10-ethyl-deaza-aminopterin)(NSC #626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B

  Authors:Hedy L. Kindler, Chandra P. Belani, James E. Herndon, II, Nicholas J. Vogelzang, Yasunosuke Suzuki, and Mark R. GreenFrom:Cancer (Vol. 86, Issue 10) Peer-Reviewed

  Nov. 15, 1999 Article

   Citation Only

• Association of interleukin-2 therapy with staphylococcal bacteremia

  Authors:Jon M. Richards, Teresa A. Gilewski, and Nicholas J. VogelzangFrom:Cancer (Vol. 67, Issue 6(1-2)) Peer-Reviewed

  Mar. 15, 1991323 words Article

   Abstract Only

• Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B

  Authors:James E. Herndon, II, Mark R. Green, A. Phillippe Chahinian, Joseph M. Corson, Yasunosuke Suzuki, and Nicholas J. VogelzangFrom:Chest (Vol. 113, Issue 3) Peer-Reviewed

  Mar. 19984,828 words Article Purpose: To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB). Patients and...

• A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

  Authors:Christopher W. Ryan, Nicholas J. Vogelzang, and Walter M. StadlerFrom:Cancer (Vol. 94, Issue 10) Peer-Reviewed

  May 15, 2002 Article

   Citation Only

• Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial

  Author:Nicholas J. VogelzangFrom:JAMA, The Journal of the American Medical Association (Vol. 274, Issue 16) Peer-Reviewed

  Oct. 25, 1995 Abstract

   Citation Only

• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  Authors:Thomas Powles, Joseph Paul Eder, Gregg D. Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, et al.From:Nature (Vol. 515, Issue 7528) Peer-Reviewed

  Nov. 27, 20144,890 words Report 1380LThere have been no major advances for the treatment of metastatic urothelial bladder cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient outcomes, especially for those in whom...

• A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients wtih metastatic renal cell carcinoma

  Authors:Apurva A. Desai, Nicholas J. Vogelzang, Brian I. Rini, Rafat Ansari, Stuart Krauss, and Walter M. StadlerFrom:Cancer (Vol. 95, Issue 8) Peer-Reviewed

  Oct. 15, 2002 Article

   Citation Only

• Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.

  Authors:Matthew D Galsky, José Ángel Arranz Arija, Aristotelis Bamias, Ian D Davis, Maria De Santis, Eiji Kikuchi, et al.From:The Lancet (Vol. 395, Issue 10236) Peer-Reviewed

  May 16, 2020868 words Article

   Abstract Only

• Prostate brachytherapy: increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data

  Authors:Anthony V. D'Amico and Nicholas J. VogelzangFrom:Cancer (Vol. 86, Issue 9) Peer-Reviewed

  Nov. 1, 1999 Editorial

   Citation Only

• A Phase II trial of Suramin monthly x 3 for Hormone-Refractory Prostate Carcinoma

  Authors:Nicholas J. Vogelzang, Theodore Karrison, Walter M. Stadler, Juan Garcia, Helene Cohn, John Kugler, et al.From:Cancer (Vol. 100, Issue 1) Peer-Reviewed

  Jan. 1, 2004 Article

   Citation Only

• Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B

  Authors:Brian L. Samuels, James E. Herndon, II, David C. Harmon, Robert Carey, Joseph Aisner, Joseph M. Corson, et al.From:Cancer (Vol. 82, Issue 8) Peer-Reviewed

  Apr. 15, 1998 Article

   Citation Only

• Prognostic factors for survival in patients treated in Phase I clinical trials

  Authors:Linda Janisch, Rosemarie Mick, Richard L. Schilsky, Nicholas J. Vogelzang, Sheila O'Brien, Michael Kut, et al.From:Cancer (Vol. 74, Issue 7) Peer-Reviewed

  Oct. 1, 1994261 words Article

   Abstract Only

• A Phase I study of intermittent infusion cladribine in patients with solid tumors

  Authors:Ken Kobayashi, Nicholas J. Vogelzang, Sheila M. O'Brien, Richard L. Schilsky, Everett E. Vokes, and Mark J. RatainFrom:Cancer (Vol. 74, Issue 1) Peer-Reviewed

  July 1, 1994319 words Article

   Abstract Only

• Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

  Authors:Edward M. Messing, Catherine M. Tangen, Seth P. Lerner, Deepak M. Sahasrabudhe, Theresa M. Koppie, Wood. David P. Jr., et al.From:JAMA, The Journal of the American Medical Association (Vol. 319, Issue 18) Peer-Reviewed

  May 8, 201847 words Article

   Citation Only

• A phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

  Authors:Everett E. Vokes, Boon C. Goh, Donna Bertucci, Nicholas J. Vogelzang, Sridhar Mani, and Mark J. RatainFrom:Cancer (Vol. 86, Issue 3) Peer-Reviewed

  Aug. 1, 1999 Article

   Citation Only

• Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

  Authors:Guru Sonpavde, Bryan H. Goldman, V.O. Speights, Seth P. Lerner, David P. Wood, Nicholas J. Vogelzang, et al.From:Cancer (Vol. 115, Issue 18) Peer-Reviewed

  Sept. 15, 2009 Clinical report

   Citation Only

• Call for revision of College of American Pathologists--mandated requirements for retention of laboratory records and materials

  Authors:Joseph D. Khoury and Nicholas J. VogelzangFrom:Archives of Pathology & Laboratory Medicine (Vol. 132, Issue 11) Peer-Reviewed

  Nov. 20081,108 words Letter to the editor 1610LTo the Editor.--The existing requirement by the College of American Pathologists (CAP) mandating laboratories to retain pathology reports, slides, and paraffin-embedded tissue blocks for a minimum of 10 years is...

• Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421

  Authors:Primo N. Lara, Jr., Benjamin Ely, David I. Quinn, Philip C. Mack, Catherine Tangen, Erik Gertz, et al.From:Journal of the National Cancer Institute (Vol. 106, Issue 4) Peer-Reviewed

  Apr. 9, 2014292 words Report

   Abstract Only

• Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies

  Authors:Sridhar Mani, Nicholas J. Vogelzang, Donna Bertucci, Walter M. Stadler, Richard L. Schilsky, and Mark J. RatainFrom:Cancer (Vol. 92, Issue 6) Peer-Reviewed

  Sept. 15, 2001 Article

   Citation Only

• A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase(r)), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer

  Authors:Nicholas J. Vogelzang, Walter M. Stadler, Mary C. Dumas, and Stanislaw M. MikulskiFrom:Investigational New Drugs (Vol. 19, Issue 3) Peer-Reviewed

  Aug. 2001140 words Author abstract, Cli... 60L

   Abstract Only